Amit Patel, MD
Pulmonary Disease · Newport News, VANPI 1699944314
Payments from drug & device makers
Across 258 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$931
- GSK$849
- AstraZeneca$750
- Jazz Pharmaceuticals Inc.$261
- Boehringer Ingelheim$230
- Grifols USA, LLC$196
- plus $2K from 33 others
What the payments were for
- Travel & lodging$2905%
- Food & beverage$5,08692%
- Education$1232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 16 | $931 |
| GSK | 52 | $849 |
| AstraZeneca | 42 | $750 |
| Jazz Pharmaceuticals Inc. | 15 | $261 |
| Boehringer Ingelheim | 12 | $230 |
| Grifols USA, LLC | 10 | $196 |
| Mylan Specialty L.p. | 13 | $179 |
| Regeneron Healthcare Solutions, Inc. | 9 | $178 |
| Genentech USA, Inc. | 8 | $176 |
| Harmony Biosciences LLC | 3 | $162 |
| Advanced Respiratory, Inc | 6 | $112 |
| Insmed, Inc. | 6 | $109 |
| Paratek Pharmaceuticals, Inc. | 5 | $108 |
| Resmed Corp | 6 | $100 |
| Optinose US, Inc. | 2 | $96 |
| Actelion Pharmaceuticals US, Inc. | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $89 |
| E.r. Squibb & Sons, L.L.C. | 1 | $78 |
| Sunovion Pharmaceuticals Inc. | 5 | $77 |
| Sanofi | 3 | $75 |
| Electromed, Inc. | 4 | $74 |
| Gilead | 4 | $65 |
| Circassia Inc. | 4 | $60 |
| Inogen, Inc. | 3 | $59 |
| ANI Pharmaceuticals, Inc. | 2 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| United Therapeutics Corporation | 2 | $40 |
| Amgen | 2 | $34 |
| Viatris Specialty LLC | 2 | $34 |
| Shire North American Group Inc | 2 | $27 |
| Pharming Healthcare, Inc. | 1 | $21 |
| Pulmonx Corporation | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Bayer | 1 | $17 |
| Inari Medical, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$533
- AIRSUPRA$119
- TRELEGY ELLIPTA$105
How this compares
$5,499 in reported general payments places this provider in the 60th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $231,512 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 147 | $192,512 |
| Spiriva RespimatTiotropium Bromide | 66 | $64,788 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $31,525 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $22,161 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $19,994 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $16,107 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $10,902 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $9,710 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 152 | $6,039 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $4,685 |
| Mycophenolate Mofetil | 14 | $1,826 |
| Montelukast Sodium | 124 | $1,167 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,061 |
| Azelastine Hcl | 40 | $1,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $89 | $231,51213 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $849 | $228,613206 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $230 | $86,94986 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $750 | $42,42754 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Newport News
- Steven NathanFalls Church$2.5M
- Shilpa JohriRichmond$1.7M
- Omar MinaiHopewell$1.3M
- Vijay SubramaniamWilliamsburg$1.3M
- Rabih HalabiFalls Church$604K
- Patricia SimeRichmond$572K
- Apostolos PerelasRichmond$567K
- Hannah MannemCharlottesville$326K
- Ray ShepherdRichmond$303K
- Eric LibreAnnandale$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.